Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels ; volume:18 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-3 ; date:12.2018
BMC cancer ; 18, Heft 1 (3.12.2018), 1-3, 12.2018
- Creator
-
Groenland, Stefanie L.
Katz, Daniela
Huitema, Alwin D. R.
Steeghs, Neeltje
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5043-9
- URN
-
urn:nbn:de:101:1-2019011921140693177476
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Groenland, Stefanie L.
- Katz, Daniela
- Huitema, Alwin D. R.
- Steeghs, Neeltje
- SpringerLink (Online service)
Other Objects (12)
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Pazopanib in advanced soft tissue sarcomas
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series